(a)blood transfusion using processed cells (excluding those using blood cell components (meaning red blood cells, white blood cells, or platelets; the same applies below in (a)) whose properties have been altered, or blood cell components produced from human or animal cells (excluding medical technology stated in (c)));

(b)hematopoietic stem cell transplantation prescribed in Article 2, paragraph (2) of the Act on the Appropriate Provision of Hematopoietic Stem Cells for Transplantation (Act No. 90 of 2012) (excluding transplantation using hematopoietic stem cells that have undergone processing that alters their properties, or transplantation using hematopoietic stem cells produced from human or animal cells (excluding the medical technology stated in (c)));

(c)medical technology using human sperm (including sperm cells and spermatocytes whose number of chromosomes is equal to that of sperm; the same applies below in this sub-item (c) and the following item), unfertilized eggs (meaning unfertilized egg cells and oocytes whose number of chromosomes is equal to that of unfertilized egg cells; the same applies below in this sub-item (c) and the following item), or embryos produced by fertilization between human sperm and unfertilized eggs, which have been cultured or otherwise processed (excluding those using embryonic stem cells derived from human sperm and unfertilized eggs collected from a human, or those cultured or otherwise processed from such embryonic stem cells (excluding those using human sperm or unfertilized eggs derived from such embryonic stem cells, or those cultured or otherwise processed from the sperm, unfertilized eggs, or embryos produced by fertilization between them));

(d)medical devices prescribed in Article 23-2-5, paragraph (1) of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960), or specially controlled medical devices or controlled medical devices designated pursuant to the provisions of Article 23-2-23, paragraph (1) of the same Act, for which an application for approval under Article 23-2-5 or Article 23-2-17, or for certification under Article 23-2-23 of the same Act (simply referred to below as "approval or certification" in this sub-item (d) and sub-item (a) of the following item), has been filed and approved or certified—limited to applications describing matters concerning the effects of the medical devices or compliance with standards for specially controlled medical devices or controlled medical devices, as specified by Order of the Ministry of Health, Labour and Welfare, in the written application (referred to below as "approved or certified medical devices" in sub-item (a) of the same item)—and only processed cells obtained by culturing or otherwise processing human or animal cells using methods related to the approval or certification (meaning methods of use, effects, and performances; the same applies below in this sub-item (d) and sub-item (a) of the same item);

(a)medical technology that uses only nucleic acids and related compounds generated using methods related to the approval or certification obtained for the approved or certified medical devices;

(b)medical technology that uses only nucleic acids and related compounds (limited to those specified by the Minister of Health, Labour and Welfare as necessary for the prevention of infectious diseases) that are pharmaceuticals prescribed in Article 2, paragraph (1) of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, intended for use in the prevention of human diseases, and are authorized to be sold, provided, or stored or displayed for the purpose of sale or provision in a foreign country as prescribed in Article 14-3, paragraph (1), item (ii) of the same Act.